COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376740
Recruitment Status : Completed
First Posted : September 15, 2006
Last Update Posted : August 23, 2011
Tel-Aviv Sourasky Medical Center
Information provided by (Responsible Party):
David B. Geffen, Soroka University Medical Center

Brief Summary:
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the aromatase inhibitor drug letrozole, after having received adjuvant tamoxifen.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: zoledronic acid Phase 3

Detailed Description:
Letrozole is an aromatase inhibitor used in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women.It has more recently been approved for use in many countries as adjuvant therapy for early breast cancer; and is often used in an adjuvant regimen following 2-3 years of tamoxifen treatment or as an extended adjuvant therapy after up to 5 years of tamoxifen. Letrozole inhibits the conversion of androgens to estrogens in vitro and in vivo. Plasma levels of estradiol and related estrogen compounds in postmenopausal patients receiving letrozole are suppressed up to 95% from baseline and are often undetectable.The estrogen deprivation in women receiving letrozole may cause increased bone resorption and bone loss.Studies comparing tamoxifen and aromatase inhibitors, in adjuvant therapy have shown an increase fracture rate, and decreased bone mineral density in patients receiving aromatase inhibitors. Zoledronic acid is an intravenously administered bisphosphonate that inhibits osteoclastic bone resorption. Intravenous bisphosphonates are effective in reducing the rate of skeletal complications, including fractures, in patients with metastatic breast cancer and other tumors when given every few weeks. Small clinical trials have given some evidence that osteoporosis can be effectively treated by one or two doses of intravenous zoledronic acid per year. This study will determine the effect of giving zoledronic acid every 6 months on the bone mineral density of patients receiving letrozole as adjuvant therapy for early breast cancer after having received adjuvant tamoxifen for at least 2.5 years. Patients will be randomized to receive zoledronic acid either at the start of letrozole therapy or when bone mineral density T score drops below - 2 standard deviation or at the occurrence of a non-trauma related fracture.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting
Study Start Date : September 2005
Actual Primary Completion Date : November 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Immediate zoledronic acid
Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
Drug: zoledronic acid
Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Other Name: Zomera, zolendronate

Active Comparator: Delayed zoledronic acid
Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
Drug: zoledronic acid
Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Other Name: Zomera, zolendronate

Primary Outcome Measures :
  1. bone mineral density
  2. bone events
  3. renal function
  4. liver function

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 82 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women with histologically documented early (non-metastatic) breast cancer
  • Previous treatment with tamoxifen for at least 2.5 years and not more than 3.5 years
  • Assigned to receive letrozole treatment
  • Karnofsky performance status ≥ 70
  • Life expectancy ≥ 16 weeks
  • Signed informed consent after full explanation of study by participating clinician and prio to any study specific procedures
  • Adjuvant or neoadjuvant chemotherapy is allowed
  • No clinical and/or radiologic evidence of distant metastases
  • No prior treatment with an aromatase inhibitor
  • Able to comply with treatment and scheduled follow-up visits
  • Age between 18 and 82 years

Exclusion Criteria:

  • Pregnant or lactating women or women with child bearing potential
  • Patients with other malignancies except except adequately treated basal cell carcinoma of the skin or in-situ cervix carcinoma
  • Active infection or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment
  • Clinical and/or radiological evidence of distant metastases.
  • Evidence of pathological fracture
  • Prior treatment with an aromatase inhibitor
  • Prior administration of any intravenous bisphosphonate during the last year.
  • Oral bisphosphonate must be discontinued within 4 weeks of enrollment
  • Administration of long-term systemic corticosteroids within the last 12 months (short term steroid treatment is allowed.)
  • Prior use of parathyroid hormone treatment for more than 1 week
  • Use of any drug known to affect the skeleton (calcitonin, mithramycin, gallium nitrate) within two weeks prior to enrollment
  • Abnormal renal function: creatinine clearance must be above 30 ml/min (calculated by Cockroft formula)
  • Evidence of metabolic bone disease( Paget's, osteogenesis imperfecta, hyperparathyroidism within the 12 months prior to enrollment)
  • Baseline lumbar spine and or total hip Bone Mineral Density T score below -2
  • Known hypersensitivity to zoledronic acid
  • Psychological, familial, sociologic, or geographic conditions which do not permit medical follow-up and compliance with the study protocol
  • White blood cell ≤ 3.0 x 10exp9 /L or granulocytes ≤ 1.5 x 10exp9/L or platelets ≤100 x 10exp9
  • Total bilirubin> 1.5 x upper normal limit, SGOT and SGPT > 2.5 x upper normal limit
  • Unable to undergo DXA bone density scanning (spine deformity, severe scoliosis, lumbar sacral spine surgery)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376740

Layout table for location information
Soroka University Medical Center
Beer Sheva, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Soroka University Medical Center
Tel-Aviv Sourasky Medical Center
Layout table for investigator information
Study Chair: Tamar Safra, M.D. Tel-Aviv Sourasky Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David B. Geffen, Director of the Oncology Ambulatory Care Clinic, Soroka University Medical Center Identifier: NCT00376740    
Other Study ID Numbers: sor440006ctil
First Posted: September 15, 2006    Key Record Dates
Last Update Posted: August 23, 2011
Last Verified: August 2011
Keywords provided by David B. Geffen, Soroka University Medical Center:
breast cancer, postmenopausal, letrozole, zoledronic acid, adjuvant,bone mineral density
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Zoledronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs